Yuyu Pharma, Inc.(KR:000220)
â‚©3,705.00-35.00 (-0.94%)
KR:000220
Yuyu Pharma, Inc. financials statements
â‚©3,705.00
At close:-35.00 (-0.94%)
Want to see KR:000220 full AI Analyst Report?
Yuyu Pharma, Inc. (000220) Ratios
Yuyu Pharma, Inc. Ratios
KR:000220's free cash flow for Q3 2026 was ₩-2.53B. For the 2026 fiscal year, KR:000220's free cash flow was decreased by ₩-6.64B and operating cash flow was ₩4.12B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.64 | 1.58 | 2.03 | 1.50 | 3.29 |
| Quick Ratio | 0.93 | 0.98 | 1.15 | 0.88 | 2.45 |
| Cash Ratio | 0.49 | 0.65 | 0.61 | 0.40 | 1.67 |
| Solvency Ratio | 0.21 | 0.20 | -0.02 | 0.01 | 0.06 |
| Operating Cash Flow Ratio | 0.27 | 0.39 | 0.01 | -0.10 | 0.15 |
| Short-Term Operating Cash Flow Coverage | 0.59 | 0.76 | 0.02 | -0.17 | 0.45 |
| Net Current Asset Value | â‚© 29.88B | â‚© 29.32B | â‚© 23.74B | â‚© 24.53B | â‚© 34.59B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.13 | 0.16 | 0.20 | 0.20 | 0.20 |
| Debt-to-Equity Ratio | 0.22 | 0.27 | 0.35 | 0.34 | 0.32 |
| Debt-to-Capital Ratio | 0.18 | 0.21 | 0.26 | 0.25 | 0.24 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.11 | 0.01 | 0.19 |
| Financial Leverage Ratio | 1.60 | 1.66 | 1.77 | 1.67 | 1.55 |
| Debt Service Coverage Ratio | 0.50 | 0.53 | 0.17 | 0.07 | 0.47 |
| Interest Coverage Ratio | 1.98 | 3.63 | 0.14 | 0.27 | 1.22 |
| Debt to Market Cap | 0.36 | 0.45 | 0.39 | 0.37 | 0.31 |
| Interest Debt Per Share | 2017.81 | 2277.85 | 2261.40 | 2524.45 | 2590.50 |
| Net Debt to EBITDA | -0.07 | -0.43 | 1.81 | 3.95 | -1.76 |
| Profitability Margins | |||||
| Gross Profit Margin | 38.29% | 38.83% | 35.37% | 38.39% | 39.20% |
| EBIT Margin | 7.82% | 9.92% | -0.55% | -0.89% | 1.55% |
| EBITDA Margin | 11.80% | 14.17% | 3.54% | 2.45% | 5.44% |
| Operating Profit Margin | 7.82% | 8.79% | 0.27% | 0.50% | 2.29% |
| Pretax Profit Margin | 6.73% | 7.50% | -3.97% | -2.74% | -0.33% |
| Net Profit Margin | 5.79% | 6.55% | -5.23% | -3.19% | -0.80% |
| Continuous Operations Profit Margin | 6.47% | 7.73% | -4.04% | -3.19% | -0.80% |
| Net Income Per EBT | 85.99% | 87.34% | 131.95% | 116.14% | 240.19% |
| EBT Per EBIT | 86.06% | 85.36% | -1492.89% | -550.83% | -14.44% |
| Return on Assets (ROA) | 3.93% | 4.20% | -3.62% | -2.27% | -0.48% |
| Return on Equity (ROE) | 6.31% | 6.96% | -6.40% | -3.79% | -0.74% |
| Return on Capital Employed (ROCE) | 7.43% | 8.17% | 0.25% | 0.53% | 1.63% |
| Return on Invested Capital (ROIC) | 6.02% | 6.63% | 0.21% | 0.41% | 1.53% |
| Return on Tangible Assets | 3.99% | 4.26% | -3.70% | -2.31% | -0.49% |
| Earnings Yield | 10.89% | 11.96% | -7.23% | -4.26% | -0.74% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.09 | 6.75 | 6.60 | 6.33 | 5.92 |
| Payables Turnover | 4.46 | 8.60 | 8.10 | 5.40 | 7.83 |
| Inventory Turnover | 2.06 | 2.11 | 2.01 | 2.15 | 2.79 |
| Fixed Asset Turnover | 1.51 | 1.48 | 1.69 | 1.71 | 1.44 |
| Asset Turnover | 0.68 | 0.64 | 0.69 | 0.71 | 0.60 |
| Working Capital Turnover Ratio | 3.74 | 2.99 | 3.28 | 2.75 | 2.01 |
| Cash Conversion Cycle | 146.92 | 184.74 | 191.98 | 160.00 | 145.94 |
| Days of Sales Outstanding | 51.51 | 54.09 | 55.33 | 57.66 | 61.63 |
| Days of Inventory Outstanding | 177.25 | 173.12 | 181.72 | 169.91 | 130.93 |
| Days of Payables Outstanding | 81.84 | 42.46 | 45.08 | 67.57 | 46.62 |
| Operating Cycle | 228.76 | 227.21 | 237.06 | 227.57 | 192.56 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 968.39 | 1541.75 | 22.68 | -375.68 | 282.51 |
| Free Cash Flow Per Share | 470.96 | 1090.43 | -252.51 | -711.47 | -140.50 |
| Dividend Paid and CapEx Coverage Ratio | 1.58 | 2.80 | 0.06 | -0.82 | 0.52 |
| Capital Expenditure Coverage Ratio | 1.95 | 3.42 | 0.08 | -1.12 | 0.67 |
| Operating Cash Flow Coverage Ratio | 0.58 | 0.74 | 0.01 | -0.16 | 0.12 |
| Operating Cash Flow to Sales Ratio | 0.11 | 0.19 | 0.00 | -0.04 | 0.04 |
| Free Cash Flow Yield | 10.43% | 24.20% | -4.72% | -11.37% | -1.80% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 9.18 | 9.62 | -13.82 | -23.45 | -135.44 |
| Price-to-Sales (P/S) Ratio | 0.53 | 0.55 | 0.72 | 0.75 | 1.08 |
| Price-to-Book (P/B) Ratio | 0.58 | 0.58 | 0.88 | 0.89 | 1.00 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 9.59 | 4.13 | -21.19 | -8.80 | -55.59 |
| Price-to-Operating Cash Flow Ratio | 4.66 | 2.92 | 235.88 | -16.66 | 27.64 |
| Price-to-Earnings Growth (PEG) Ratio | 1.80 | -0.04 | -0.31 | -0.06 | 1.04 |
| Enterprise Value Multiple | 4.44 | 3.43 | 22.24 | 34.45 | 18.04 |
| Enterprise Value | 73.74B | 64.72B | 108.07B | 117.23B | 113.54B |
| EV to EBITDA | 4.44 | 3.43 | 22.24 | 34.45 | 18.04 |
| EV to Sales | 0.52 | 0.49 | 0.79 | 0.84 | 0.98 |
| EV to Free Cash Flow | 9.44 | 3.67 | -23.07 | -9.94 | -50.64 |
| EV to Operating Cash Flow | 4.59 | 2.59 | 256.79 | -18.82 | 25.18 |
| Tangible Book Value Per Share | 8278.80 | 8152.55 | 6256.32 | 7216.63 | 7804.17 |
| Shareholders’ Equity Per Share | 7791.89 | 7738.49 | 6046.12 | 7045.31 | 7787.50 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.04 | -0.03 | -0.02 | -0.16 | -1.40 |
| Revenue Per Share | 8491.63 | 8227.60 | 7394.63 | 8376.07 | 7247.01 |
| Net Income Per Share | 491.47 | 538.86 | -387.00 | -266.90 | -57.67 |
| Tax Burden | 0.86 | 0.87 | 1.32 | 1.16 | 2.40 |
| Interest Burden | 0.86 | 0.76 | 7.27 | 3.10 | -0.21 |
| Research & Development to Revenue | 0.03 | 0.02 | 0.05 | 0.06 | 0.03 |
| SG&A to Revenue | 0.14 | 0.13 | 0.12 | 0.14 | 0.14 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Income Quality | 1.76 | 2.42 | -0.06 | 1.41 | -4.90 |
Currency in KRW
